Expertise in
3
conditions

Jan Gerstoft

Copenhagen, DK 
Expertise in
3
conditions
Copenhagen, DK 

Overview

Jan Gerstoft practices practicing medicine in Copenhagen, Denmark.

Gerstoft is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses HIV/AIDS, Hepatitis C, Hepatitis, and Syphilis.

They are actively involved in clinical research, co-authoring 207 peer reviewed articles and participating in 2 clinical trials.

Locations

Copenhagen, 2100, Denmark
Other Locations
Rigshospitalet, Denmark
Hvidovre, Denmark
Herlev, Denmark
Kobenhavn O, 2100, Denmark
Oby, 2100, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 1 Less Clinical Trial

207 Total Publications

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial).
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial).
Journal: BMC infectious diseases
Published: May 18, 2025

Frequently Asked Questions about Jan Gerstoft

Is Jan Gerstoft a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Jan Gerstoft is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jan Gerstoft participate in research or clinical trials?

Yes. Jan Gerstoft has published 207 articles and abstracts on conditions like HIV/AIDS. You can view a list of Jan Gerstoft's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gerstoft's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile